Recombinant goat pox virus expressing PPRV H protein.
- Author:
Weiye CHEN
1
;
Linmao QU
;
Sen HU
;
Qianqian HU
;
Qian ZHANG
;
Haibing ZHI
;
Kehe HUANG
;
Zhigao BU
Author Information
1. State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute of Chinese Academy of Agricultural Sciences, Harbin 150001, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Capripoxvirus;
genetics;
immunology;
Goat Diseases;
immunology;
prevention & control;
virology;
Goats;
Hemagglutinins, Viral;
genetics;
immunology;
metabolism;
Peste-des-Petits-Ruminants;
immunology;
prevention & control;
Peste-des-petits-ruminants virus;
genetics;
immunology;
Recombinant Proteins;
genetics;
immunology;
metabolism;
Vaccines, Combined;
immunology;
Vaccines, Synthetic;
immunology;
Viral Vaccines;
immunology
- From:
Chinese Journal of Biotechnology
2009;25(4):496-502
- CountryChina
- Language:Chinese
-
Abstract:
The purpose of the study is to construct recombinant goat pox virus (GPV) expressing Peste des petits ruminants virus (PPRV) H protein, and to evaluate the immunization effect. Recombinant GPV containing PPRV H gene (rGPV-PPRV-H) was selected and purified by gpt and eGFP utilizing plaque purification, and the final selected recombinant GPV was proved to be purified by PCR. Immunofluorescence and Western blotting showed that the recombinant virus could express H protein of PPRV while infecting lamb testis cells. Six goats were immunized with 2 x 10(6) PFU rGPV-PPRV-H through intradermal injection, and were immunized for the second time at 28 days with the same dose recombinant virus after first immunization. Serum was collected after immunization, and was analyzed for the neutralization antibodies. 21 days after first immunization, the neutralization antibodies of GPV were 40, 80, > or = 80, > or = 80, 40, > or = 80 in turn, and neutralization antibodies of PPRV were 80, 80, 80, 80, 40, 40, 10 in turn; 14 days after second immunization, the neutralization antibodies of GPV were all > or = 80, and the neutralization antibodies of PPRV were > 80, 80, > 80, 80, 80 and 40 in turn. This study established a foundation for the industrialization of the PPRV recombinant GPV vaccine.
